Retatrutide 40 mg

Retatrutide 40 mg Injection Pen is a pharmaceutical-grade preparation containing 40 mg of Retatrutide, delivered via subcutaneous injection using a prefilled, multi-dose pen device. It can be used in treating Type 2 Diabetes Mellitus and Weight management. It  works as a triple agonist receptor GIP/ GLP-1 and glucagon receptor agonist that boosts insulin, reduces appetite, allows gastric emptying, and increases energy burn. 

Key Features

How Does Retatrutide 40 mg work?

Retatrutide is a single peptide formulated to activate 3 metabolic hormone receptors at once:

• GLP-1 receptor agonism: Slows gastric emptying, increases satiety signals to the brain, enhances glucose-dependent insulin secretion
• GIP receptor agonism: Enhances insulin secretion and may improve fat metabolism in preclinical models
• Glucagon receptor agonism: Increases energy expenditure and hepatic fat oxidation in research settings

Usage

• It can be used in dealing with Type-2 Diabetes.
• It can be used in managing weight.

Dosage

• Starting at 1-2 mg once weekly, with gradual increases every 4 weeks up to 12 mg once weekly.
• Do not self-titrate. Rapid dose escalation increases risk of GI side effects and pancreatitis.

Side Effects

• Constipation
• Abdominal pain
• Decreased appetite
• Nausea
• Diarrhea
• Vomiting
• Heartburn
• Flatulence
• Redness
• Itching
• Dizziness

Interactions

• It may interact adversely with other oral medications resulting in slowing gastric emptying this can delay absorption of other oral drugs.
• It also interacts with insulin/Sulfonylureas the concomitant use increases hypoglycaemia risk.
• Warfarin monitoring is need as it may affects the absorption.
• Alcohol may lead to increase the risk of other side effects.

Pharmacokinetics

• It may reach the peak plasma concentration Tmax at just 24-72 hours post injection.
• Proteolytic degradation occurs to form small peptides and amino acids, similar to other GLP-1 peptides. This is followed by metabolism.
• Excretion, via kidney.

Precautions

Talk to your doctor before use if you have:

• Personal/family history of medullary thyroid carcinoma or MEN2.
• History of pancreatitis, gallbladder disease, or severe GI disease.
• Type 1 diabetes or diabetic ketoacidosis history.
• Severe renal impairment dehydration risk.
• Pregnancy, planning pregnancy, or breastfeeding weight loss not recommended; fetal risk unknown.

Conclusion

Retatrutide 40 mg Injection Pen contains 40 mg of Retatrutide, delivered via subcutaneous injection using a prefilled, multi-dose pen device. It can be used in treating Type 2 Diabetes Mellitus and Weight management. It works  as a triple agonist receptor GIP/ GLP-1 and Glucagon receptor agonist that boosts insulin, reduces appetite, may allow gastric emptying, and increase energy burn. It may have some side effects like vomiting, nausea, diarrhea, constipation, abdominal pain and decreased appetite.

FAQs

• What is the use of Retatrutide 40 mg?
  Retatrutide 40 mg is used for weight management and Type 2 Diabetes.
• How does Retatrutide 40 mg work?
  Retatrutide 40 mg works as a triple agonist receptor GIP/ GLP-1 and Glucagon receptor agonist that boosts insulin, reduces appetite, may allow gastric emptying, and increase energy burn.
• What can be the possible side effects of Retatrutide 40 mg?
  The possible side effects can be vomiting, nausea, diarrhea, constipation, abdominal pain and decreased appetite.
• Who should avoid taking Retatrutide 40 mg?
  The one with medical history of Medullary thyroid carcinoma (MTC) or MEN2, the one with hypersensitive to Retatrutide and Type 1 Diabetes should avoid taking any such medications.
• What can be the onset of action of Retatrutide?
  It reaches the peak plasma concentration at just 24-72 hours after SubQ injection.

Note: Retatrutide is a prescription medicine and this is for educational purposes only. Consult your healthcare provider prior to using any of these medications.